| Website | lipella.com |
| Category | BioTech |
| Phone | 412.894.1915 |
| Employees | |
| Description | Intravesical therapy |
| Total | $360k |
| Unattributed, 12/06 Pittsburgh Life Sciences Greenhouse | $120k |
| Unattributed, 4/08 Pittsburgh Life Sciences Greenhouse | $240k |
Lipella is a development-stage biotechnology company. Lipella’s products in development target intravesical therapy, which is a method of providing local treatments directly to the urinary bladder lumen via urethral catheterization. Indications we target include interstitial cystitis (also known as painful bladder syndrome), overactive bladder, and superficial bladder cancer.
Interstitial cystitis is a chronic, painful, inflammatory condition of the bladder wall that affects over 1 million people in the United States. Its cause is unknown and there is no cure. Treatment options exist, but a majority of cases are refractive to existing therapies.
